Medical AI

A new report reveals Europe's medically-focused cannabis market is finally waking, creating a new global blueprint but also intense competition and price wars.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

A landmark Novo Nordisk study finds 2 in 5 heart patients have hidden inflammation, a major risk for heart attack and stroke despite standard treatments.

French biotech TreeFrog Therapeutics isn't just replacing cells; it's implanting pre-wired networks. Their novel 3D microtissue shows faster, more extensive brain repair.

With game-changing Phase III data for iza-bren in breast cancer and a deep pipeline, SystImmune is poised to make a major impact at ASCO 2026.

Gene Solutions' AI-driven multi-omics liquid biopsy platform makes waves at a major oncology conference, finding a ready market in Taiwan.

At SLAS 2026, MGI Tech unveiled intelligent platforms for proteomics and clinical automation, signaling a major push to accelerate scientific discovery.

With new CEO Andrew Zeringue, Theromics aims to tackle cancer recurrence with its HeatSYNC gel, a novel approach in the booming ablation market.

A powerful new combination therapy from Junshi Biosciences and RemeGen gains approval in China, offering unprecedented hope for urothelial carcinoma patients.

A third straight Computex award cements Wincomm's leadership, blending powerful on-device AI with a pioneering eco-friendly design in medical workstations.

A non-invasive therapy boasts up to 91% success for chronic pain, but patients often face a major hurdle: paying for the promising treatment themselves.

Dr. Craig Tendler's move to Predicta Biosciences signals a major shift, blending pharma expertise with biotech innovation to revolutionize cancer care.

A novel drug is in clinical trials for depression, moving beyond neurotransmitters to target the brain's fundamental energy production and repair mechanisms.

IGI announces ISB 2301, a first-in-class antibody targeting three tumor antigens and activating both T and NK cells for a new assault on solid tumors.

A first-in-class drug for anxiety has entered patient trials, offering a novel approach that could reshape mental healthcare for millions.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

New projects leverage AI, gene therapy advances, and diverse workforce initiatives to bolster America's manufacturing and secure its talent pipeline.

An award-winning technology is transforming how hospitals treat a deadly diabetic complication in children, minimizing errors and improving patient safety.

With a new $17.5M financing, Forlong Biotechnology accelerates its promising IL-15 and IL-18 cancer drugs, aiming to redefine post-PD-1 immunotherapy.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.